Basic fibroblast growth factor(Kyoto University)(Basic fibroblast growth factor(Kyoto University))

概要

基本信息

药物类型

生长因子

别名

靶点

bFGF

作用机制

bFGF调节剂(成纤维细胞生长因子2调节剂)

治疗领域

心血管疾病

在研适应症-

非在研适应症

外周动脉疾病

原研机构

Kyoto University

在研机构-

非在研机构

Kyoto University

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Basic fibroblast growth factor(Kyoto University) 相关的临床试验

JPRN-jRCTs061220098 / Recruiting临床2期IIT

Evaluation of the regeneration facilitating effects of facial nerve decompression using basic fibroblast growth factor for severe facial paralysis

开始日期2023-02-20

申办/合作机构

The Japan Wool Textile Co., Ltd.

JPRN-UMIN000013629 / CompletedN/AIIT

Injection laryngoplasty using basic fibroblast growth factor for the treatment of deficient glottal closure - Injection laryngoplasty using basic fibroblast growth factor for the treatment of deficient glottal closure

开始日期2013-04-01

申办/合作机构-

JPRN-jRCT1092220038 / Completed临床1/2期IIT

Trials in chronic skin ulcers using new collagen substitutes incorporating basic fibroblast growth factor

开始日期2010-05-10

申办/合作机构

Kyoto University Hospital

100 项与 Basic fibroblast growth factor(Kyoto University) 相关的临床结果

登录后查看更多信息

100 项与 Basic fibroblast growth factor(Kyoto University) 相关的转化医学

登录后查看更多信息

100 项与 Basic fibroblast growth factor(Kyoto University) 相关的专利（医药）

登录后查看更多信息

457

项与 Basic fibroblast growth factor(Kyoto University) 相关的文献（医药）

2024-09-01·Blood transfusion = Trasfusione del sangue

Platelet rich plasma for facial rejuvenation: an overview of systematic reviews.

Review

作者: Pupella, Simonetta ; Pati, Ilaria ; De Angelis, Vincenzo ; Cruciani, Mario ; Masiello, Francesca

BACKGROUNDPlatelet-rich plasma (PRP) as a non-surgical therapy for facial rejuvenation is increasingly adopted. This article aims to review the literature and critically appraise the available evidence regarding the efficacy and safety of PRP for facial rejuvenation.MATERIAL AND METHODSAn overview of systematic reviews (SRs) of PRP use for facial rejuvenation. The methodological quality of the SRs was assessed using the AMSTAR-2 checklist; quality of the evidence from the trials included in each SR was appraised following the GRADE approach.RESULTSThirteen SRs published between 2015 and 2023, reporting data from 114 overlapping reports, based on 28 individual primary studies (18 uncontrolled reports), were included in this umbrella review. Eight primary studies evaluated PRP in combination with other treatments (laser therapy, fat grafting, hyaluronic acid, basic fibroblast growth factor), and 20 PRP monotherapy. Most of the included primary studies were uncontrolled, and meta-analysis for outcomes related to facial rejuvenation was conducted in only 1 of the 13 SRs, showing that patients treated with PRP as an adjunct treatment have increased satisfaction over controls without PRP (mean difference, 0.63; 95% confidence intervals (CIs) 0.25/1; p=0-001; low certainty of evidence due to risk of bias (ROB) and inconsistency). No other quantitative data were available from the SRs, although 4 SRs concluded in a descriptive way reveal that PRP combined with laser therapy increased subject satisfaction and skin elasticity, and decreased the erythema index (very low certainty of evidence due to imprecision, unsystematic clinical observations, and ROB). The occurrence of adverse events was a predefined outcome in only 2 SRs (15%). Almost all the SRs demonstrated poor compliance with the AMSTAR 2 items, and the confidence in the results of SRs was graded as low or critically low in 12 of the 13 SRs.DISCUSSIONThe available evidence is insufficient to suggest firm conclusions about the use of PRP, alone or in combination with other treatments, in promoting facial rejuvenation.

2024-09-01·Colloids and Surfaces B: Biointerfaces

Recombinant collagen coating 3D printed PEGDA hydrogel tube loading with differentiable BMSCs to repair bile duct injury

Article

作者: Yang, Yijun ; Gao, Yuanhui ; Cheng, Qiuhua ; Zhang, Jianquan ; Zhang, Xiaoyu ; Lei, Zhongwen ; Xiang, Yang

Bile duct injury presents a significant clinical challenge following hepatobiliary surgery, necessitating advancements in the repair of damaged bile ducts is a persistent issue in biliary surgery. 3D printed tubular scaffolds have emerged as a promising approach for the repair of ductal tissues, yet the development of scaffolds that balance exceptional mechanical properties with biocompatibility remains an ongoing challenge. This study introduces a novel, bio-fabricated bilayer bile duct scaffold using a 3D printing technique. The scaffold comprises an inner layer of polyethylene glycol diacrylate (PEGDA) to provide high mechanical strength, and an outer layer of biocompatible, methacryloylated recombinant collagen type III (rColMA) loaded with basic fibroblast growth factor (bFGF)-encapsulated liposomes (bFGF@Lip). This design enables the controlled release of bFGF, creating an optimal environment for the growth and differentiation of bone marrow mesenchymal stem cells (BMSCs) into cholangiocyte-like cells. These cells are instrumental in the regeneration of bile duct tissues, evidenced by the pronounced expression of cholangiocyte differentiation markers CK19 and CFTR. The PEGDA//rColMA/bFGF@Lip bilayer bile duct scaffold can well simulate the bile duct structure, and the outer rColMA/bFGF@Lip hydrogel can well promote the growth and differentiation of BMSCs into bile duct epithelial cells. In vivo experiments showed that the scaffold did not cause cholestasis in the body. This new in vitro pre-differentiated active 3D printed scaffold provides new ideas for the study of bile duct tissue replacement.

2024-07-01·Advanced Healthcare Materials

BV2 Membrane‐Coated PEGylated‐Liposomes Delivered hFGF21 to Cortical and Hippocampal Microglia for Alzheimer's Disease Therapy

Article

作者: Lu, Cui-Tao ; Zhao, Ying-Zheng ; Kim, Kwonseop ; Wang, Heng-Cai ; Han, Yong-Hui ; Xu, Ling ; Yu, Xi-Chong ; Lin, Yi ; Yang, Wei

AbstractMicroglia‐mediated inflammation is involved in the pathogenesis of Alzheimer's disease (AD), whereas human fibroblast growth factor 21 (hFGF21) has demonstrated the ability to regulate microglia activation in Parkinson's disease, indicating a potential therapeutic role in AD. However, challenges such as aggregation, rapid inactivation, and the blood–brain barrier hinder its effectiveness in treating AD. This study develops targeted delivery of hFGF21 to activated microglia using BV2 cell membrane‐coated PEGylated liposomes (hFGF21@BCM‐LIP), preserving the bioactivity of hFGF21. In vitro, hFGF21@BCM‐LIP specifically targets Aβ1‐42‐induced BV2 cells, with uptake hindered by anti‐VCAM‐1 antibody, indicating the importance of VCAM‐1 and integrin α4/β1 interaction in targeted delivery to BV2 cells. In vivo, following subcutaneous injection near the lymph nodes of the neck, hFGF21@BCM‐LIP diffuses into lymph nodes and distributes along the meningeal lymphatic vasculature and brain parenchyma in amyloid‐beta (Aβ1‐42)‐induced mice. Furthermore, the administration of hFGF21@BCM‐LIP to activated microglia improves cognitive deficits caused by Aβ1‐42 and reduces levels of tau, p‐Tau, and BACE1. It also decreases interleukin‐6 (IL‐6) and tumor necrosis factor‐α (TNF‐α) release while increasing interleukin‐10 (IL‐10) release both in vivo and in vitro. These results indicate that hFGF21@BCM‐LIP can be a promising treatment for AD, by effectively crossing the blood–brain barrier and targeting delivery to brain microglia via the neck‐meningeal lymphatic vasculature‐brain parenchyma pathways.

100 项与 Basic fibroblast growth factor(Kyoto University) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
外周动脉疾病	临床1期	-	Kyoto University	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


REBIOS (ISC2014)	N/A	缺血性卒中	171	Basic Fibroblast Growth Factor (Diabetic patients)	壓壓廠願範醖鏇夢衊築(鏇繭膚繭積淵廠衊獵簾) = 鬱醖蓋淵築醖鹹網壓網觸壓獵積鏇願製簾觸構 (鹽鏇壓積糧鬱鹽壓積選 )	-	2014-02-01
				Basic Fibroblast Growth Factor (Non-diabetic patients)	壓壓廠願範醖鏇夢衊築(鏇繭膚繭積淵廠衊獵簾) = 醖醖齋夢獵鏇衊鏇餘積觸壓獵積鏇願製簾觸構 (鹽鏇壓積糧鬱鹽壓積選 )
ASGCT2009	N/A	-	-	Basic Fibroblast Growth Factor Gene	壓積衊鏇遞衊壓淵鹽構(夢構簾餘鑰範顧衊憲築) = 鹹窪襯遞積鹽淵鏇鏇積窪獵積積憲鏇網膚鑰構 (艱淵糧壓顧繭鬱襯窪窪 )	-	2009-05-01
ARVO2002	N/A	病理性新生血管	18	Medpor(R) soaked with bFGF	憲鑰製願築齋築鑰膚膚(積糧簾艱鹽艱糧觸鬱醖) = 簾顧衊築壓網鹽鹹鹽築鏇獵遞製襯顧網觸積鹹 (襯窪衊鏇蓋憲網憲醖憲 )	积极	2002-12-01
				Basic Fibroblast Growth Factor	憲鑰製願築齋築鑰膚膚(積糧簾艱鹽艱糧觸鬱醖) = 淵憲網選顧遞顧蓋選網鏇獵遞製襯顧網觸積鹹 (襯窪衊鏇蓋憲網憲醖憲 )